{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T08:21:18Z","timestamp":1794385278065,"version":"4.9.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up. Exacerbation rate, asthma symptoms, maintenance oral corticosteroid (OCS) use and lung function were evaluated, among other variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 204 SEA patients were evaluated. Mean (standard deviation,\u00a0SD) age of the study population was 56.4 (12.4) years, 62.3% were women and mean (SD) duration of asthma was 15.1 (12.7) years. Median (Q1\u2013Q3) follow-up duration was 19.5 (14.2\u201324.2) months. At baseline, 72.6% of the overall population (OP) presented blood eosinophil counts\u2009\u2265\u2009300 cells\/\u00b5L; 36.8% had comorbid chronic rhinosinusitis with nasal polyps (CRSwNP); 84.8% reported at least one severe exacerbation, and 29.1% were OCS-dependent. At 1 year of follow-up, patients receiving benralizumab treatment had a 85.6% mean reduction in exacerbations from baseline, and 81.4% of patients achieved zero exacerbations. We also found a clinically relevant mean (SD) increase in pre-bronchodilator (BD) FEV\n                      <jats:sub>1<\/jats:sub>\n                      of 331 (413) mL, with 66.7% of patients achieving a pre-BD FEV\n                      <jats:sub>1<\/jats:sub>\n                      increase\u2009\u2265\u2009100 mL, and 46.3% of patients achieving a pre-BD FEV\n                      <jats:sub>1<\/jats:sub>\n                      \u2009\u2265\u200980% of predicted. Regarding symptom control, 73.8% of the OP obtained an ACT score\u2009\u2265\u200920 points. After 1 year of follow-up, mean reduction in the daily OCS dose was 70.5%, and complete OCS withdrawal was achieved by 52.8% of the OCS-dependent patients. Almost half (43.7%) of the OP on benralizumab met all four criteria for clinical remission. Patients with concomitant CRSwNP obtained similar or enhanced outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data support the real-world benefits of benralizumab in SEA patients, and particularly in those with concomitant CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NCT04648839.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-023-02539-7","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T11:03:10Z","timestamp":1695898990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study"],"prefix":"10.1186","volume":"24","author":[{"given":"Alicia","family":"Padilla-Galo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Moya Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Aus\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Carazo Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Garc\u00eda-Moguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Velasco-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"And\u00fajar-Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Casas-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mart\u00ednez-Morag\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Vera Solsona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"S\u00e1nchez-Toril L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tris\u00e1n Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Blanco Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Valverde-Monge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Valencia Azcona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Palop Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Nuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"S\u00e1nchez Tena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Resler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Luz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Levy Naon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2539_CR1","unstructured":"Global Initiative for Asthma. 2023 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: https:\/\/ginasthma.org\/2023-gina-main-report\/"},{"issue":"2","key":"2539_CR2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"issue":"2","key":"2539_CR3","doi-asserted-by":"crossref","first-page":"T150","DOI":"10.1016\/j.arbres.2021.05.032","volume":"58","author":"V Plaza","year":"2022","unstructured":"Plaza V, et al. [Translated article] spanish Asthma Management Guidelines (GEMA) v.5.1. Highlights and controversies. Arch Bronconeumol. 2022;58(2):T150\u20138.","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"2539_CR4","doi-asserted-by":"crossref","first-page":"100192","DOI":"10.1016\/j.opresp.2022.100192","volume":"4","author":"FJ Alvarez-Guti\u00e9rrez","year":"2022","unstructured":"Alvarez-Guti\u00e9rrez FJ, et al. Documento de consenso de asma grave en adultos. Actualizaci\u00f3n 2022. Open Respiratory Archives. 2022;4(3):100192.","journal-title":"Open Respiratory Archives"},{"issue":"1","key":"2539_CR5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","volume":"17","author":"RY Suruki","year":"2017","unstructured":"Suruki RY, et al. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"2539_CR6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","volume":"73","author":"M Kerkhof","year":"2018","unstructured":"Kerkhof M, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. 2018;73(2):116\u201324.","journal-title":"Thorax"},{"key":"2539_CR7","doi-asserted-by":"crossref","unstructured":"Dom\u00ednguez-Ortega J et al. Uso de glucocorticoides sist\u00e9micos para el tratamiento del asma grave: Consenso multidisciplinar espa\u00f1ol. Open Respiratory Archives. 2022;4(4).","DOI":"10.1016\/j.opresp.2022.100202"},{"issue":"3","key":"2539_CR8","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","volume":"160","author":"LG Heaney","year":"2021","unstructured":"Heaney LG, et al. Eosinophilic and noneosinophilic asthma: an Expert Consensus Framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814\u201330.","journal-title":"Chest"},{"issue":"1","key":"2539_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/ACI.0000000000000870","volume":"23","author":"WW Busse","year":"2023","unstructured":"Busse WW. Consequences of severe asthma exacerbations. Curr Opin Allergy Clin Immunol. 2023;23(1):44\u201350.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"2539_CR10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","volume":"145","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757\u201365.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2539_CR11","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","volume":"9","author":"JW Upham","year":"2021","unstructured":"Upham JW, et al. Defining a severe asthma Super-Responder: findings from a Delphi process. J Allergy Clin Immunol Pract. 2021;9(11):3997\u20134004.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2539_CR12","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344\u201353. e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"10056","key":"2539_CR13","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115\u201327.","journal-title":"Lancet"},{"issue":"10056","key":"2539_CR14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128\u201341.","journal-title":"Lancet"},{"issue":"25","key":"2539_CR15","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, et al. Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"2539_CR16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46\u201359.","journal-title":"Lancet Respir Med"},{"key":"2539_CR17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/JAA.S227170","volume":"12","author":"JM FitzGerald","year":"2019","unstructured":"FitzGerald JM, et al. Two-year Integrated Efficacy and Safety Analysis of Benralizumab in severe asthma. J Asthma Allergy. 2019;12:401\u201313.","journal-title":"J Asthma Allergy"},{"issue":"4","key":"2539_CR18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/02770903.2019.1705333","volume":"58","author":"A Bourdin","year":"2021","unstructured":"Bourdin A, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2021;58(4):514\u201322.","journal-title":"J Asthma"},{"issue":"12","key":"2539_CR19","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","volume":"9","author":"S Korn","year":"2021","unstructured":"Korn S, et al. Integrated Safety and Efficacy among Patients receiving Benralizumab for Up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381\u201392. e4.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2539_CR20","unstructured":"Gu\u00eda Espa\u00f1ola para el Manejo del Asma (GEMA) v.5.3. Available at: https:\/\/www.gemasma.com\/"},{"issue":"4","key":"2539_CR21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","volume":"181","author":"WC Moore","year":"2010","unstructured":"Moore WC, et al. Identification of asthma phenotypes using cluster analysis in the severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2539_CR22","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","volume":"46","author":"DE Shaw","year":"2015","unstructured":"Shaw DE, et al. Clinical and inflammatory characteristics of the european U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308\u201321.","journal-title":"Eur Respir J"},{"issue":"3","key":"2539_CR23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, et al. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133\u201341.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2539_CR24","doi-asserted-by":"crossref","first-page":"105947","DOI":"10.1016\/j.rmed.2020.105947","volume":"166","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947.","journal-title":"Respir Med"},{"key":"2539_CR25","doi-asserted-by":"crossref","unstructured":"Bleecker ER et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4).","DOI":"10.1183\/13993003.00936-2018"},{"key":"2539_CR26","doi-asserted-by":"crossref","first-page":"205873842095085","DOI":"10.1177\/2058738420950851","volume":"34","author":"N Lombardo","year":"2020","unstructured":"Lombardo N, et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. Int J Immunopathol Pharmacol. 2020;34:2058738420950851.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"3","key":"2539_CR27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","volume":"9","author":"TW Harrison","year":"2021","unstructured":"Harrison TW, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9(3):260\u201374.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2539_CR28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","volume":"113","author":"RA Nathan","year":"2004","unstructured":"Nathan RA, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59\u201365.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2539_CR29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/02770900701752615","volume":"44","author":"JM Vega","year":"2007","unstructured":"Vega JM, et al. Validation of the spanish version of the Asthma Control Test (ACT). J Asthma. 2007;44(10):867\u201372.","journal-title":"J Asthma"},{"issue":"2","key":"2539_CR30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","volume":"159","author":"JE Kavanagh","year":"2021","unstructured":"Kavanagh JE, et al. Real-world effectiveness of Benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496\u2013506.","journal-title":"Chest"},{"key":"2539_CR31","doi-asserted-by":"crossref","first-page":"101830","DOI":"10.1016\/j.pupt.2019.101830","volume":"58","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, et al. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. Pulm Pharmacol Ther. 2019;58:101830.","journal-title":"Pulm Pharmacol Ther"},{"issue":"12","key":"2539_CR32","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1111\/all.14441","volume":"75","author":"A Renner","year":"2020","unstructured":"Renner A, et al. Benralizumab rapidly improves asthma control in austrian real-life severe eosinophilic asthmatics. Allergy. 2020;75(12):3272\u20135.","journal-title":"Allergy"},{"issue":"1","key":"2539_CR33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12890-020-01220-9","volume":"20","author":"A Padilla-Galo","year":"2020","unstructured":"Padilla-Galo A, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2539_CR34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.18176\/jiaci.0793","volume":"32","author":"JC Miralles Lopez","year":"2022","unstructured":"Miralles Lopez JC, et al. Effectiveness of Benralizumab in severe eosinophilic asthma under conditions of routine clinical practice. J Investig Allergol Clin Immunol. 2022;32(3):220\u20133.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2539_CR35","doi-asserted-by":"crossref","first-page":"881218","DOI":"10.3389\/falgy.2022.881218","volume":"3","author":"M D\u2019Amato","year":"2022","unstructured":"D\u2019Amato M, et al. Benralizumab in patients with severe eosinophilic asthma with and without chronic Rhinosinusitis with nasal polyps: an ANANKE Study post-hoc analysis. Front Allergy. 2022;3:881218.","journal-title":"Front Allergy"},{"issue":"6","key":"2539_CR36","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","volume":"10","author":"DJ Jackson","year":"2022","unstructured":"Jackson DJ, et al. Benralizumab effectiveness in severe asthma is Independent of previous biologic use. J Allergy Clin Immunol Pract. 2022;10(6):1534\u201344. e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl 66","key":"2539_CR37","first-page":"4620","volume":"60","author":"S Korn","year":"2022","unstructured":"Korn S, et al. Early response and remission with benralizumab in patients with severe asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in the prospective real-world ImPROve Asthma study. Eur Respir J. 2022;60(suppl 66):4620.","journal-title":"Eur Respir J"},{"issue":"2","key":"2539_CR38","doi-asserted-by":"crossref","first-page":"AB13","DOI":"10.1016\/j.jaci.2022.12.045","volume":"151","author":"D Jackson","year":"2023","unstructured":"Jackson D, et al. Asthma clinical remission with Benralizumab in an Integrated analysis of the real-world XALOC-1 study. J Allergy Clin Immunol. 2023;151(2):AB13.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2539_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","volume":"144","author":"R Kaur","year":"2019","unstructured":"Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1\u201312.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2539_CR40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","volume":"6","author":"JM FitzGerald","year":"2018","unstructured":"FitzGerald JM, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51\u201364.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2539_CR41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/cea.12881","volume":"47","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, et al. The current and future role of biomarkers in type 2 cytokine-mediated asthma management. Clin Exp Allergy. 2017;47(2):148\u201360.","journal-title":"Clin Exp Allergy"},{"key":"2539_CR42","doi-asserted-by":"crossref","unstructured":"Dagher R et al. Novel mechanisms of action contributing to benralizumab\u2019s potent anti-eosinophilic activity. Eur Respir J. 2022;59(3):2004306","DOI":"10.1183\/13993003.04306-2020"},{"issue":"2","key":"2539_CR43","doi-asserted-by":"crossref","first-page":"AB28","DOI":"10.1016\/j.jaci.2019.12.813","volume":"145","author":"P Franco","year":"2020","unstructured":"Franco P, et al. Inhaled corticosteroid use and its implication in peripheral eosinophil level. J Allergy Clin Immunol. 2020;145(2):AB28.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2539_CR44","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","volume":"20","author":"CM Prazma","year":"2019","unstructured":"Prazma CM, et al. Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis. Respir Res. 2019;20(1):83.","journal-title":"Respir Res"},{"key":"2539_CR45","doi-asserted-by":"crossref","unstructured":"Bleecker ER et al. Clinical implications of longitudinal blood Eosinophil Counts in patients with severe asthma. J Allergy Clin Immunol Pract. 2023;11(6):1805\u201313.","DOI":"10.1016\/j.jaip.2023.02.020"},{"key":"2539_CR46","doi-asserted-by":"crossref","first-page":"950883","DOI":"10.3389\/fmed.2022.950883","volume":"9","author":"C Caruso","year":"2022","unstructured":"Caruso C, et al. Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: an ANANKE study post hoc analysis. Front Med (Lausanne). 2022;9:950883.","journal-title":"Front Med (Lausanne)"},{"key":"2539_CR47","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2147\/JAA.S358705","volume":"15","author":"A Gomez-Bastero Fernandez","year":"2022","unstructured":"Gomez-Bastero Fernandez A, et al. Effectiveness of switching to Benralizumab in severe refractory eosinophilic asthma. J Asthma Allergy. 2022;15:727\u201335.","journal-title":"J Asthma Allergy"},{"key":"2539_CR48","doi-asserted-by":"crossref","unstructured":"Scioscia G et al. Switching Biological Therapies in severe asthma. Int J Mol Sci. 2023;24(11):9563.","DOI":"10.3390\/ijms24119563"},{"key":"2539_CR49","doi-asserted-by":"crossref","unstructured":"Scioscia G et al. Benralizumab in patients with severe eosinophilic asthma: a Multicentre Real-Life experience. J Clin Med. 2023;12(13):4362.","DOI":"10.3390\/jcm12134362"},{"key":"2539_CR50","doi-asserted-by":"crossref","unstructured":"Bourdin A et al. ERS\/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. Eur Respir J. 2019;54(3):1900900.","DOI":"10.1183\/13993003.00900-2019"},{"issue":"2","key":"2539_CR51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaip.2021.10.059","volume":"10","author":"R Buhl","year":"2022","unstructured":"Buhl R, et al. Effective management of severe asthma with biologic medications in adult patients: a Literature Review and International Expert Opinion. J Allergy Clin Immunol Pract. 2022;10(2):422\u201332.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"2539_CR52","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","volume":"23","author":"F Menzella","year":"2022","unstructured":"Menzella F, et al. ChAracterization of ItaliaN severe uncontrolled asthmatic patieNts key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respir Res. 2022;23(1):36.","journal-title":"Respir Res"},{"issue":"12","key":"2539_CR53","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","volume":"9","author":"S Nolasco","year":"2021","unstructured":"Nolasco S, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world Multicenter Study. J Allergy Clin Immunol Pract. 2021;9(12):4371\u201380. e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"2539_CR54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker ER, et al. Systematic literature review of systemic corticosteroid use for Asthma Management. Am J Respir Crit Care Med. 2020;201(3):276\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2539_CR55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/03007995.2016.1233101","volume":"33","author":"P Lefebvre","year":"2017","unstructured":"Lefebvre P, et al. Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin. 2017;33(1):57\u201365.","journal-title":"Curr Med Res Opin"},{"key":"2539_CR56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/JAA.S176026","volume":"11","author":"DB Price","year":"2018","unstructured":"Price DB, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193\u2013204.","journal-title":"J Asthma Allergy"},{"issue":"4","key":"2539_CR57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2500\/aap.2015.36.3863","volume":"36","author":"JL Zazzali","year":"2015","unstructured":"Zazzali JL, et al. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy Asthma Proc. 2015;36(4):268\u201374.","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"2539_CR58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pulmoe.2020.10.002","volume":"27","author":"C Chaves Loureiro","year":"2021","unstructured":"Chaves Loureiro C, et al. Reducing oral corticosteroids in severe asthma (ROSA Project): a nationwide portuguese consensus. Pulmonology. 2021;27(4):313\u201327.","journal-title":"Pulmonology"},{"issue":"7","key":"2539_CR59","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1164\/rccm.202007-2721OC","volume":"203","author":"CM Suehs","year":"2021","unstructured":"Suehs CM, et al. Expert Consensus on the tapering of oral corticosteroids for the treatment of Asthma. A Delphi Study. Am J Respir Crit Care Med. 2021;203(7):871\u201381.","journal-title":"Am J Respir Crit Care Med"},{"key":"2539_CR60","doi-asserted-by":"crossref","unstructured":"Menzies-Gow A et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5(3).","DOI":"10.1183\/23120541.00009-2019"},{"issue":"1","key":"2539_CR61","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","volume":"10","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47\u201358.","journal-title":"Lancet Respir Med"},{"key":"2539_CR62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/JAA.S297273","volume":"14","author":"C Pelaia","year":"2021","unstructured":"Pelaia C, et al. Therapeutic Effects of Benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression. J Asthma Allergy. 2021;14:163\u201373.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"2539_CR63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-022-02295-2","volume":"23","author":"C Almonacid","year":"2023","unstructured":"Almonacid C, et al. Geographical differences in the use of oral corticosteroids in patients with severe asthma in Spain: heat map based on existing databases analyses. BMC Pulm Med. 2023;23(1):3.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2539_CR64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaci.2006.01.011","volume":"117","author":"M Schatz","year":"2006","unstructured":"Schatz M, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549\u201356.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2539_CR65","first-page":"1","volume":"33","author":"L de Perez","year":"2023","unstructured":"de Perez L, et al. Response to monoclonal antibodies in Asthma: definitions, potential reasons for failure, and Therapeutic Options for suboptimal response. J Investig Allergol Clin Immunol. 2023;33(1):1\u201313.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"2539_CR66","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","volume":"9","author":"K Eger","year":"2021","unstructured":"Eger K, et al. Long-term therapy response to Anti-IL-5 biologics in severe Asthma-A real-life evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194\u2013200.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"2539_CR67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.15586\/aei.v50i6.704","volume":"50","author":"JC Miralles-L\u00f3pez","year":"2022","unstructured":"Miralles-L\u00f3pez JC, et al. Analysis of response of severe eosinophilic asthmatic patients to benralizumab. Allergol Immunopathol (Madr). 2022;50(6):163\u20138.","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"1","key":"2539_CR68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12931-021-01758-0","volume":"22","author":"A Padilla-Galo","year":"2021","unstructured":"Padilla-Galo A, et al. Real-life cost-effectiveness of benralizumab in patients with severe asthma. Respir Res. 2021;22(1):163.","journal-title":"Respir Res"},{"key":"2539_CR69","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.rmed.2020.106080","volume":"171","author":"D Bagnasco","year":"2020","unstructured":"Bagnasco D, et al. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171:106080.","journal-title":"Respir Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02539-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02539-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02539-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T17:15:04Z","timestamp":1700327704000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02539-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02539-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Capitalization in title and correct version of ESM files have been updated","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP-G: Personal fees and non-financial support: AstraZeneca, Novartis, GSK, Sanofi-Genzyme and Teva; ALN: Personal fees: AstraZeneca; non-financial support: Sanofi-Genzyme; IMC: Personal fees: AstraZeneca and Novartis; non-financial support: AstraZeneca; PA: Personal fees and non-financial support: AstraZeneca, Sanofi-Genzyme and GSK; LCF: Personal fees: AstraZeneca, Novartis, GSK and Teva; non-financial support: Sanofi-Genzyme; IG-M: Personal fees and non-financial support: AstraZeneca, GSK, Teva, Novartis, Sanofi-Genzyme; JLV-G: Personal fees: AstraZeneca, Sanofi-Genyme and GSK; non-financial support: AstraZeneca; RA-E: Personal fees and non-financial support: AstraZeneca, GSK, Teva, Novartis and Sanofi-Genzyme; FC-M: Personal fees and non-financial support: AstraZeneca, GSK, Novartis, Sanofi-Genzyme and Teva; EM-M: Personal fees: AstraZeneca, GSK and Sanofi-Genzyme; non-financial support: AstraZeneca; CMR: Personal fees: AstraZeneca, Novartis, GSK, Teva and Sanofi-Genzyme; non-financial support: AstraZeneca, GSK and Teva; EVS: Personal fees: AstraZeneca, GSK, Novartis and Sanofi-Genzyme; non-financial support: Sanofi-Genzyme and GSK; FS-TL: Personal fees: AstraZeneca, GSK, Novartis, Teva and Sanofi-Genzyme; non-financial support: AstraZeneca, GSK, Novartis and Sanofi-Genzyme; ATA: Personal fees and non-financial support: AstraZeneca, GSK, Sanofi-Genzyme and Novartis; MBA: Personal fees and non-financial fees from AstraZeneca, Teva, Sanofi-Genzyme and GSK; MV-M: Personal fees and non-financial support: AstraZeneca and GSK; BVA: Personal fees: AstraZeneca, Novartis, GSK and Sanofi-Genzyme; non-financial support: Teva; MPC: Personal fees and non-financial support: AstraZeneca, GSK, Teva, Novartis and Sanofi-Genzyme; JN, JST, GR and EL: employees of AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice (ICH\/GCP) and applicable regulatory requirements. Written informed consent was obtained from all included patients. Ethics committee approval was obtained on 20 September 2020. Patient medical information obtained for this study was confidential and could only be disclosed to the researchers and third parties involved as provided in the informed consent form signed by the patients. Data from all participating sites were combined into a single anonymized dataset for analysis. AstraZeneca maintains confidentiality standards through the assignment of a unique subject identification number for each patient enrolled in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"235"}}